On April 19th, the EHC marked World Haemophilia Day in Strasbourg, France with an event dedicated to the latest Wildbad Kreuth IV consensus recommendations on optimal haemophilia care throughout Europe! These recommendations are the result of a series of meetings, during which experts from 36 countries took part in numerous discussions, reviewing of trends, presentations and workshops in order to address current challenges in haemophilia treatment and care. By highlighting this achievement, the EHC also brought attention to the real issue – getting these recommendations implemented by governments.
We are also very excited to have had the opportunity during the event to unveil important details around the PARTNERS programme, including signing a Consensus Agreement with three pharmaceutical companies. One of the main goals of the project is to increase access to replacement therapies in European countries that provide little or no such treatment to their haemophilia patients.
A special thank you to the European Directorate for the Quality of Medicines and Healthcare (EDQM), an agency of the Council of Europe, for their support and hosting of EHCs’ event.
For all details, quotes and highlights of the day, please refer to the EHC WHD Event 2017 Press Release.